TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Brief Summary: The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.


Options:
A: Inclusion Criteria:

* Clinical diagnosis of chronic pruritus and unresponsive to current therapies

Exclusion Criteria:

* Have chronic liver or renal disease
B: Inclusion Criteria:

1. Patients age: over 18 years
2. itch over VAS 3

Exclusion Criteria:

1. pregnancy, lactating women
2. drug abuse
3. active psychosomatic and psychiatric disease
4. active cancer.
5. topical application of tacrolimus, pimecrolimus, corticosteroids or capsaicin two weeks before study start
6. intake of antihistamines, corticosteroids, cyclosporine A and other immunosuppressants, naltrexone, UV-therapy two weeks before study start
7. participation in any other research study during the previous 4 weeks.
C: Inclusion Criteria:

* Are 18 years or older with diagnosis for at least 12 months of moderate to severe plaque psoriasis covering as least 10%of body surface area
* a Psoriasis Area and Severity Index (PASI) score of 12 and are considered to be candidates for systemic or light therapy
* No evidence of active or latent tuberculosis

Exclusion Criteria:

* Non-plaque or drug induced forms of psoriasis
* cannot discontinue current oral, injectible or topical therapy for psoriasis or cannot discontinue phototherapy (PUVA or UVB)
* any uncontrolled significant medical condition
D: Inclusion Criteria:

* 18 years or older with diagnosis for at least 12 months of moderate to severe plaque psoriasis covering at least 10% of body surface area
* A Psoriasis Area and Severity Index (PASI) score of 12 or greater
* Are considered to be candidates for systemic or light therapy
* Have no evidence of active or latent tuberculosis

Exclusion Criteria:

* Non-plaque or drug-induced forms of psoriasis
* Cannot discontinue current oral, injectible or topical therapy for psoriasis or cannot discontinue phototherapy (PUVA or UVB)
* Any uncontrolled significant medical condition

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Efficacy of Nebulised Hypertonic Saline (3%) Among Children With Mild to Moderately Severe Bronchiolitis - A Double Blind Randomized Controlled Trial.
Brief Summary: To assess the efficacy of nebulized 3% hypertonic saline in improving clinical severity scores among children aged 6 weeks to 24 months with bronchiolitis.


Options:
A: Inclusion Criteria:

* Age 8 weeks through 23 months
* First episode of wheezing associated with respiratory distress and upper respiratory tract infection.
* Respiratory Distress Assessment Instrument (RDAI) rating of ≥4 and ≤15 after initial albuterol nebulization per standard care
* Pediatric Emergency Medicine (PEM) physician does not plan additional bronchodilator therapy within the hour after initial assessment.
* Parental/guardian permission (informed consent)

Exclusion Criteria:

* Subjects with prior history of wheezing or asthma or who have received bronchodilator therapy prior to the current illness
* Chronic lung or heart disease
* Critically ill infants requiring immediate airway stabilization
* Non-English speaking parent/guardian
* Inability to take nebulized medications
B: Inclusion Criteria:

* Patients 0-12 months of age admitted to the hospital with a diagnosis of bronchiolitis.

Exclusion Criteria:

* status asthmaticus
* chronic cardiopulmonary disease
* Trisomy 21
* immunodeficiency or transplant recipient
* neuromuscular disease
* admission directly to the intensive care unit
* previous use of nebulized hypertonic saline less than 12 hours prior to presentation
* previous enrollment in the study in the 72 hours prior to presentation
C: Inclusion Criteria:

* Age 6 weeks to 24 Months.
* First episode of wheezing
* Fever, cough and watery nasal discharge

Exclusion Criteria :

* Any underlying cardiovascular disease.
* Prior wheezing.
* Clinical Severity Score \> 9.
* Atopic dermatitis, allergic rhinitis or asthma.
* Oxygen saturation (SpO2) \<85% on room air.
* Obtunded consciousness.
* Previous treatment with bronchodilators within 4 hours.
* Any steroid therapy within 48 Hours.
D: Inclusion Criteria:

* Previously healthy infants under 1 year of age
* Admitted to hospital with a clinical diagnosis of acute bronchiolitis, following the UK definition of an infant with an apparent viral respiratory tract infection associated with airways obstruction manifest by hyperinflation, tachypnoea and subcostal recession with widespread crepitations on auscultation
* Requiring supplemental oxygen therapy on admission

Exclusion Criteria:

* Wheezy bronchitis or asthma - children with an apparent viral respiratory infection and wheeze with no or occasional crepitations
* Previous lower respiratory tract infections
* Risk factors for severe disease \[gestation \<32 weeks, immunodeficiency, neurological and cardiac conditions, chronic lung disease\]
* Subjects where the carer's English is not fluent and translational services are not available
* Requiring admission to high dependency or intensive care units at the time of recruitment

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Efficacy of Nebulised Hypertonic Saline (3%) Among Children With Mild to Moderately Severe Bronchiolitis - A Double Blind Randomized Controlled Trial.
Brief Summary: To assess the efficacy of nebulized 3% hypertonic saline in improving clinical severity scores among children aged 6 weeks to 24 months with bronchiolitis.


Options:
A: Inclusion Criteria:

* Previously healthy infants under 1 year of age
* Admitted to hospital with a clinical diagnosis of acute bronchiolitis, following the UK definition of an infant with an apparent viral respiratory tract infection associated with airways obstruction manifest by hyperinflation, tachypnoea and subcostal recession with widespread crepitations on auscultation
* Requiring supplemental oxygen therapy on admission

Exclusion Criteria:

* Wheezy bronchitis or asthma - children with an apparent viral respiratory infection and wheeze with no or occasional crepitations
* Previous lower respiratory tract infections
* Risk factors for severe disease \[gestation \<32 weeks, immunodeficiency, neurological and cardiac conditions, chronic lung disease\]
* Subjects where the carer's English is not fluent and translational services are not available
* Requiring admission to high dependency or intensive care units at the time of recruitment
B: Inclusion Criteria:

* Age 6 weeks to 24 Months.
* First episode of wheezing
* Fever, cough and watery nasal discharge

Exclusion Criteria :

* Any underlying cardiovascular disease.
* Prior wheezing.
* Clinical Severity Score \> 9.
* Atopic dermatitis, allergic rhinitis or asthma.
* Oxygen saturation (SpO2) \<85% on room air.
* Obtunded consciousness.
* Previous treatment with bronchodilators within 4 hours.
* Any steroid therapy within 48 Hours.
C: Inclusion Criteria:

* Patients age 6 weeks to ≤ 18 months
* Diagnosed with bronchiolitis (defined as viral respiratory illness and first episode of wheeze)
* BSS score of ≥ 4

Exclusion Criteria:

* A previous history of wheezing;
* diagnosis of asthma;
* any use of bronchodilators within 2 h of presentation
* gestational age ≤ 34 weeks
* history of congenital heart disease
* chronic pulmonary or chronic renal disease
* oxygen saturation of ≤ 85% at the time of recruitment
* severe disease requiring intensive care unit admission
* inability to obtain informed consent
D: Inclusion Criteria:

* Patients 0-12 months of age admitted to the hospital with a diagnosis of bronchiolitis.

Exclusion Criteria:

* status asthmaticus
* chronic cardiopulmonary disease
* Trisomy 21
* immunodeficiency or transplant recipient
* neuromuscular disease
* admission directly to the intensive care unit
* previous use of nebulized hypertonic saline less than 12 hours prior to presentation
* previous enrollment in the study in the 72 hours prior to presentation

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effectiveness of a Leisure Time Physical Activity Intervention on the Overweight and the Obesity in Schoolchildren. The Cuenca's Study
Brief Summary: The purpose of this study is to evaluate the effectiveness of a recreational physical activity intervention (RPAI) for reducing the prevalence of overweight/obesity and other cardiovascular risk factors


Options:
A: Inclusion Criteria:

* Elementary school students in K-3 grade in the Bronx, New York

Exclusion Criteria:

* Inability to participate in basic exercise program
* Students whose parents signed the opt-out letter
B: Inclusion Criteria:

* passive commuted to school last 6 months, own a bike

Exclusion Criteria:

* less than 2 km to school
C: The Boards of Governors (community participatory organ in each school) and the children's parents will inform of the study's aims and methods, and give their written consent to the children's participation. Similarly, the study will present classroom-by-classroom to the children, and their oral consent will obtain. Participant children will be free of serious learning difficulties, or physical or mental disorders, that could impede participation in the scheduled physical activities.
D: Inclusion Criteria:

* Children in the 1. grade of secondary General Schools or Intermediate Schools with written consent from the parents in the greater Munich area

Exclusion Criteria:

* Children without written consent from their parents

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Haemodynamic Assessment at Primary Caesarean Section After Administration of Carbetocin Versus Oxytocin: a Doubleblind Randomized Trail
Brief Summary: The purpose of this study is to evaluate the immediate effects of carbetocin and oxytocin on maternal hemodynamic parameters (heart rate and blood pressure) in a non-invasive setup (TaskeForce®-Monitor) during primary Caesarean section.


Options:
A: Inclusion Criteria:

* home delivery
* presence of Community Health Officer at time of delivery

Exclusion Criteria:

* None
B: Inclusion Criteria:

* \> 24 weeks, viable pregnancy, singleton or twins

Exclusion Criteria:

* No consent
* Contraindication to oxytocin
* Antepartum fetal demise
* Intrapartum use of concentrated oxytocin
* Planned cesarean
* DIC or coagulopathy
C: Inclusion Criteria:

* healthy women
* singleton pregnancy
* caesarean section under regional anaesthesia
* older than 18 years
* written informed consent

Exclusion Criteria:

* emergency caesarean section
* secondary caesarean section due to fetal distress
* comorbidities (cardiovascular, kidney or liver disorder, epilepsy)
* obstetric diseases (hypertension, (pre-)eclampsia)
* uterine malformation (including uterine fibroids)
* bleeding disorder
* known hypersensitivity to carbetocin or oxytocin
* fetal malformation
D: Inclusion Criteria:

* Healthy pregnant women undergoing elective caesarean section with regional anesthesia

Exclusion Criteria:

---Women with

* placenta praevia
* placental abruption
* multiple gestation
* pregnancy related complications and disorders (i.e. preeclampsia, gestational diabetes)
* pre-existing diseases (e.g. insulin-dependent diabetes, cardiovascular or renal diseases, thyroid disease
* taking medication with known impact on the cardiovascular system
* undergoing caesarean section with general anesthesia
* secondary caesarean section

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Cosmesis and Body Image After Single Port Laparoscopic or Conventional Laparoscopic Cholecystectomy: A Double Blinded Randomised Controlled Trial
Brief Summary: Laparoscopic Cholecystectomy (LC) is the treatment of choice for symptomatic gallstone disease. Single-port access cholecystectomy (SL) has been recently introduced using only one, trans-umbilical placed port. The method has been denominated as ''scarless.'' However, it is unknown whether SL significantly improves body and cosmesis images as well as the quality of life (QoL), reported directly by the patients. Furthermore SL promises to reduce postoperative pain and to be cost-effective due a faster postoperative recovery.

The aim of this Double Blind Randomized Controlled Trial (RCT) is to demonstrate whether SL is superior to LC in improving patients', body and cosmesis images as well as QoL and to analyse cost-efficiency.

Based on the sample size calculations, a total of 110 patients will be randomised to either LC or SL. The primary endpoint will be the cosmetic score. Costs, pain, time to convalescence, quality of life and complications and will also be compared as secondary endpoints.

This study will provide evidence-based patient-oriented information regarding the SL procedure and its further use.


Options:
A: Inclusion Criteria:

* Age more than 18 years

Exclusion Criteria:

* Contraindication to laparoscopy
* Liver disease
* Cognitive trouble
B: Inclusion Criteria:

* Need for cholecystectomy

Exclusion Criteria:

* Need for cholangiogram
C: Inclusion Criteria:

* Patients with symptomatic cholelithiasis, admitted for laparoscopic cholecystectomy

Exclusion Criteria:

* Patients with acute cholecystitis
* Patients with extensive upper abdominal incisions
* Patients with body mass index \>30
* Patients on regular analgesic medication
D: Inclusion Criteria:

1. Patients above 18 years of age for elective cholecystectomy
2. Written informed consent from the subject
3. INR \< 1.4, platelet count \> 50'000/mcl

Exclusion Criteria:

1. Women in pregnancy
2. Contraindications on ethical grounds
3. Severe coagulopathy (platelet \< 50'000/mcl, double medication on platelet antagonists (Plavix and Aspirin), INR \> 1.4
4. liver cirrhosis
5. Enrolment of the investigator, his/her family members, employees and other dependent persons

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Cervical Foley Plus Vaginal Misoprostol Versus Vaginal Misoprostol for Cervical Ripening and Labor Induction: A Randomized Trial
Brief Summary: The purpose of this study is to compare the efficacy of the combination of the supracervical foley bulb and vaginal misoprostol to vaginal misoprostol alone for labor induction. We hypothesize that use of the foley bulb plus vaginal misoprostol will result in shorter induction to delivery time.


Options:
A: Inclusion Criteria:

* Reproductive aged women, pregnant, term gestation (\>37 weeks), undergoing induction of labor, cervical exam acceptable as a candidate for Foley balloon catheter placement (Bishop score \<5), cephalic fetal presentation.

Exclusion Criteria:

* Regular contractions on admission, rupture of membranes, previous uterine scar, low-lying placenta (measured \<3cm to internal os), Bishop score \> 5, contraindication to attempt at vaginal birth, non-English/Spanish speaking, unable to give consent.
B: Inclusion Criteria:

* singleton pregnancy
* vertex presentation
* unfavorable cervix(Bishop's score less than or equal to 6)
* greater than 24 weeks gestation

Exclusion Criteria:

* fetal malpresentation
* multifetal gestation
* spontaneous labor
* more than 5 uterine contractions in 10 minutes
* contraindication to prostaglandins
* non-reassuring fetal heart rate tracing
* intrauterine growth restriction
* anomalous fetus
* fetal demise
* previous cesarean delivery or other significant uterine surgery
C: Inclusion Criteria

* Term 37 weeks or more, singleton in cephalic presentation
* Age 18 years and older
* Patient admitted for induction of labor

Exclusion Criteria:

* Malpresentation
* Preterm labor less than 37 weeks of gestation
* Patients with fetal anomalies
* Premature rupture of membranes
* If the cervix is closed and unable to place the foley bulb
* Multiple gestation
* Non-reassuring fetal heart tracing
* Contraindication to misoprostol
* Contraindication to vaginal delivery (i.e. placenta previa, vasa previa, active vaginal bleeding, marginal previa, macrosomia, etc). History of prior uterine surgery such as cesarean section or myomectomy
D: Inclusion Criteria:

* Induction of labor is indicated
* Gestational age between 24 - 42 weeks
* Singleton pregnancy
* Bishop score less than 7

Exclusion Criteria:

* Any contraindication for vaginal delivery
* Previous cesarean delivery
* Low lying placenta
* Rupture of membranes
* Fetal malformations incompatible with life
* intrauterine fetal death
* Amnionitis
* Genital viral infection (HIV, hepatitis C virus

  , hepatitis B virus)
* Allergy to latex

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: EFFECTIVENESS OF A MULTIFACTORIAL INTERVENTION PROGRAM TO REDUCE FALLS INCIDENCE AMONG COMMUNITY-LIVING ELDERLY PEOPLE
Brief Summary: The purpose of this study is to determine the effectiveness of a multifactorial intervention program to prevent falls among the elderly as compared to a brief intervention.


Options:
A: Inclusion Criteria:

* Patients aged 65 years and over
* Patients with a high risk profile (at least one fall event in the last 12 months, Berg scale score ≤ 45 and at least one fall event during in-hospital stay) of recurrent falling
* Patients discharged from the Institute of Fondazione Salvatore Maugeri, IRCCS after a period of rehabilitation and living independently

Exclusion Criteria:

* Patients' inability to sign the informed consent
* Patients living in a nursing home
* Patients permanently bedridden or fully dependent on a wheelchair
* Patients with cancer
* Patients with Mini Mental Examination State (MMSE) \< 18
* Patients with MMSE \< 24 lacking of caregiver at home
* Patients with neurological impairment (i.e. aphasia and neglect)
B: Inclusion Criteria:

* At least one fall in the last 6 months
* Living in their own home or in a home for the aged
* Availability of a primary caregiver caring for the patient at least once a week
* Ability to walk 15 meters independently (use of a walking aid is permitted)
* Life expectancy of more than 6 months, as judged by their geriatrician

Exclusion Criteria:

* Dyads of patients and caregivers in whom outcome assessment is highly unlikely to succeed, for example because they proved not to be able to register falls in the three months before randomization, will be excluded
* MMSE score of less than 15
* On the waiting list for a nursing home
C: Inclusion Criteria:

* Patients residing in the community

Exclusion Criteria:

* to be institutionalized
* Immobilized or bedridden
* Present a terminal disease or severe psychiatric illness
* Have contraindications to physical exercise
D: Inclusion Criteria:

* Subjects born in 1924 of one of the 7 participating health centers and noninstitutionalized

Exclusion Criteria:

* Institutionalized

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Applying Mobile Persuasive Technologies to Increase Physical Activity in Women
Brief Summary: The primary purpose of this study is to assess the efficacy of the mobile phone-based physical activity intervention on increasing physical activity compared to the control group.


Options:
A: Inclusion Criteria:

* Ability to speak and read English
* Current patient of a physician participating in this study (if selecting a new physician, may deliberately select one that is involved in the study, in order to participate)
* Ability to complete all written surveys
* Accessible for follow-up telephone surveys
* Ability to undergo exercise testing

Exclusion Criteria:

* Currently participating in another research study
* Planning to move out of the Philadelphia area
* Unable to walk without pain
* Pregnant or planning to become pregnant in the year following study entry
* Excessive drinking
* Coronary heart disease
* Congestive heart failure
* Peripheral vascular disease
* Cerebrovascular disease
* Chronic obstructive pulmonary disease
* Arrhythmia
* Recurrent seizures
* Dizziness
* Balance problems
* Psychoses
B: Inclusion Criteria:

* Residents of the 20 most deprived neighbourhoods in the city of Sheffield
* Aged 40 to 64 years
* Not achieving the current recommended activity level (30 mins of moderate activity on at least 5 days) assessed using the SPAQ (Lowther, 1999) and wishing to have support to become more active

Exclusion Criteria:

* Have increased their physical activity level by at least 30 mins of moderate or vigorous activity per week (assessed using the SPAQ) since initial assessment of activity level
* Capacity to give written informed consent to trial participation
C: Inclusion Criteria:

* Sedentary lifestyle at work and/or during leisure time
* Intend to be physically active
* Female, age \>25 to 69
* Access to a home telephone or a mobile phone
* Speak and read English

Exclusion Criteria:

* Known medical conditions or other physical problems that need special attention in an exercise program
* Plan a trip abroad during the first 4 months of the study period.
* Pregnant/Delivered a baby during the last 6 months
* Known severe hearing or speech problem
* Body Mass Index (BMI) \> 43.0 kg/m2
* Currently participate in lifestyle modification programs or research studies that may potentially confound the results of the study
* History of bariatric surgery or future plans for bariatric surgery in the next 12 months
D: Inclusion Criteria:

* mother of infant aged 2-12 months
* sedentary
* healthy, able to do moderate intensity physical activity
* BMI = 18.5-40
* not planning to become pregnant in next year
* woman aged 18-45
* able speak and read English

Exclusion Criteria:

* pregnant
* planning to leave Oahu, Hawaii in the next year (permanently move away)
* a diagnosis of cancer, coronary heart disease (including atrial fibrillation), insulin-dependent diabetes mellitus (IDDM), and other atherosclerotic cardiovascular diseases (e.g., stroke),

Answer: C